METHOD FOR DIFFERENTIAL DIAGNOSIS OF ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL CANCER Russian patent published in 2024 - IPC G01N33/68 G01N33/574 A61B5/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gynaecology, and can be used for differential diagnosis of endometrial hyperplasia and endometrial cancer. Anamnesis is collected, blood is sampled. Following factors are determined: age, presence of unspecified vaginal haemorrhage during one year, serum levels of immune complex α2-glycoprotein with IgG (ABG-IgG), mcg/ml, VEGF, IU/ml, TNF-α, pg/ml. Screening score (SS) is established for each factor, namely: at age: up to 20 years – 0 SS, 20-25 years – 5 SS, 26-30 years – 10 SS, 31-35 years – 15 SS, 36-40 years – 20 SS, 41-45 years – 25 SS, 46-50 years – 30 SS, 51-55 years – 35 SS, 56-60 years – 40 SS, 61-65 years – 45 SS, 66-70 years – 50 SS, 71-75 years – 55 SS, 76 years and older – 60 SS; in the presence of unspecified vaginal bleeding: there is an unspecified vaginal bleeding – 40 SS, no unspecified vaginal bleeding – 0 SS; with ABG-IgG: up to 1 mcg/ml – 0 SS, from 1.0 to 1.5 mcg/ml – 13 SS, from 1.6 to 2.0 mcg/ml – 26 SS, from 2.1 to 2.5 mcg/ml – 39 SS, from 2.6 to 3.0 mcg/ml – 52 SS, from 3.1 to 3.5 mcg/ml – 65 SS, from 3.6 to 4.0 mcg/ml – 78 SS, 4.1 mcg/ml and more – 91 SS; at VEGF: to 100 MU/ml – 10 SS, from 100 to 200 MU/ml – 20 SS, from 200 to 300 MU/ml – 30 SS, from 300 to 400 MU/ml – 40 SS, from 400 to 500 MU/ml – 50 SS, from 500 to 600 MU/ml – 60 SS, from 600 to 700 MU/ml – 70 SS, from 700 to 900 MU/ml – 80 SS, 900 MU/ml and more – 90 SS; at TNF-α: to 1.0 pg/ml – 7 SS, from 1.1 to 2.0 pg/ml – 13 SS, from 2.1 to 3.0 pg/ml – 20 SS, from 3.1 to 4.0 pg/ml – 27 SS, from 4.1 to 5.0 pg/ml – 34 SS, from 5.1 to 6.0 pg/ml – 40 SS, from 6.1 to 7.0 pg/ml – 47 SS, from 7.1 to 8.0 pg/ml – 54 SS, 8.1 pg/ml and more – 61 SS. Derived values of the factors are summed up. If the total score is less than 140, the absence of cancer and endometrial hyperplasia is diagnosed. If the total score is from 141 to 230, endometrial hyperplasia is diagnosed. If the total score is more than 231, endometrial cancer is diagnosed.

EFFECT: method provides the possibility of increasing the effectiveness of differential diagnosis of endometrial hyperplasia, endometrial cancer or their absence in the patient, as well as selecting the optimal management and treatment approach by using the clinical characteristics and biomarkers calculated in numerical equivalent as their significance increases.

1 cl, 5 dwg, 5 tbl, 3 ex